POD1UM-303: Phase 3 Evidence Redefining First-Line Therapy

This segment highlights the pivotal POD1UM-303 trial and its impact on first-line management of advanced SCAC. Historically, systemic chemotherapy has been the treatment backbone. Earlier regimens such as cisplatin plus 5-fluorouracil were eventually supplanted by carboplatin and paclitaxel following randomized phase 2 data showing similar efficacy with improved tolerability. However, the absence of phase 3 evidence left a significant gap in the treatment landscape.

POD1UM-303 represents a major advancement as one of the first phase 3 trials in this setting. The study evaluated the addition of the PD-1 inhibitor retifanlimab to carboplatin and paclitaxel in patients with newly diagnosed advanced disease. Patients were randomized to receive chemo-immunotherapy or chemotherapy alone, with progression-free survival (PFS) as the primary endpoint and overall survival (OS) as a key secondary endpoint. Importantly, crossover to immunotherapy was permitted.

The addition of retifanlimab improved outcomes across multiple measures. Median PFS increased from 7.4 to 9.3 months, and objective response rates improved from approximately 44% to 56%, which is clinically meaningful for symptomatic patients with high disease burden. Updated results also demonstrated a substantial overall survival benefit, with median OS improving from approximately 20–22 months with chemotherapy alone to nearly 33 months with the combination.

Investigators noted that the magnitude of OS improvement, approximately 10 to 11 months, likely reflects the durable benefit achieved in a subset of patients who respond particularly well to immunotherapy. These findings support earlier integration of immunotherapy rather than reserving it for later lines and have led to NCCN category 1 recommendation of carboplatin, paclitaxel, and retifanlimab as the new first-line standard of care.